Follow-up Line Therapy with Cabozantinib in locally advanced or metastatic Urothelial Carcinoma following Immunotherapy Failure

被引：0
|
作者：
Rexer, H. [1 ]
Bartsch, G. [2 ]
Ohlmann, C. -H. [3 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Univ Klin Mainz UMM, Urolog Klin & Poliklin, LKP, Mainz, Germany
[3] Deutsch Krebsgesell eV, Organgruppensprecher Arbeitsgemeinschaft Urol Onk, Berlin, Germany
来源：
UROLOGE | 2020年 / 59卷 / 03期
关键词：
D O I：
10.1007/s00120-020-01145-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：388 / 389
页数：2
相关论文
共 50 条
  • [1] First or Follow-Up Line Therapy in metastatic or non-resectable Urothelial Carcinoma
    Rexer, H.
    Ohlmann, C. -H.
    Stenzl, A.
    AKTUELLE UROLOGIE, 2019, 50 (03) : 234 - 235
  • [2] Maintenance therapy for locally advanced or metastatic urothelial carcinoma
    Rexer, H.
    Banek, S.
    Merseburger, A.
    UROLOGIE, 2024, 63 (02): : 208 - 209
  • [3] First line therapy for locally advanced or metastatic urothelial cancer
    Rexer, H.
    Ohlmann, C. -H.
    Gschwend, J.
    UROLOGE, 2017, 56 (10): : 1331 - 1332
  • [4] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    ONKOLOGE, 2012, 18 (01): : 70 - 71
  • [5] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    ONKOLOGE, 2011, 17 (07): : 638 - 639
  • [6] Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
    Meza, Luis
    Malhotra, Jasnoor
    Favorito, Crystal
    Pal, Sumanta K.
    FUTURE ONCOLOGY, 2021, 18 (01) : 21 - 33
  • [7] Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
    Loriot, Y.
    Necchi, A.
    Park, S. H.
    Garcia-Donas, J.
    Huddart, R.
    Burgess, E.
    Fleming, M.
    Rezazadeh, A.
    Mellado, B.
    Varlamov, S.
    Joshi, M.
    Duran, I.
    Tagawa, S. T.
    Zakharia, Y.
    Zhong, B.
    Stuyckens, K.
    Santiago-Walker, A.
    De Porre, P.
    O'Hagan, A.
    Avadhani, A.
    Siefker-Radtke, A. O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 338 - 348
  • [8] Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up
    Loriot, Yohann
    O'Hagan, Anne
    Siefker-Radtke, Arlene O.
    FUTURE ONCOLOGY, 2024, 20 (05) : 231 - 243
  • [9] Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Park, Se Hoon
    Garcia-Donas, Jesus
    Huddart, Robert A.
    Burgess, Earle F.
    Fleming, Mark T.
    Kalebasty, Arash Rezazadeh
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    Tagawa, Scott T.
    Zakharia, Yousef
    Akapame, Sydney
    Santiago-Walker, Ademi E.
    Monga, Manish
    O'Hagan, Anne
    Loriot, Yohann
    LANCET ONCOLOGY, 2022, 23 (02): : 248 - 258
  • [10] Erdafitinib for locally advanced or metastatic urothelial carcinoma
    Siefker-Radtke, Arlene O.
    Loriot, Yohann
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (11) : 824 - 825
12345